Sofinnova Venture Partners — 2017 Investments
2 investments dated 2017 · listed companies and verified rows first · show all
Developing broad-spectrum antifungal agents for invasive fungal infections.
BiotechSan Diego, US
Mitchell Mutz(Executive Officer, Director)
BoardChrysa Mineo(Director)Jack Florio(Director)Elaine Heron(Director)Santosh Vetticaden(Director)Karen Talmadge(Director)
Board seatAnand Mehra· per SEC Form D · $102.7M raise · filed Jan 2020
Co-investorsNew Enterprise Associates (NEA)Pappas CapitalRiverVest Venture PartnersSofinnova Ventures
HealthtechSan Francisco, US
Matthew F. Krummel, Ph.D.(Director)Steven P. James(Executive Officer, Director, Promoter)Leon Chen, Ph.D.(Director)Carol Gallagher(Director)Joshua Resnick, M.D.(Director)
Board seatMichael Powell· per SEC Form D · $62M raise · filed Dec 2017
Co-investorsMission Bay CapitalMission BiocapitalNew Enterprise Associates (NEA)OUP (Osage University Partners)Sofinnova Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.